ArticleResearch and reports in urology2025
Clinical Outcomes of Avelumab Maintenance Following Full-Dose, Reduced-Dose Cisplatin, or Carboplatin-Based Chemotherapy in Advanced Urothelial Carcinoma.
Article in Research and reports in urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative safety signals of carboplatin and cisplatin in lung cancer: a pharmacovigilance study based on FAERS.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Avelumab maintenance therapy is a standard of care for patients with advanced urothelial carcinoma (UC) who achieve disease control following platinum-based chemotherapy. However, the influence of induction chemotherapy intensity on avelumab outcomes remains unclear. Materials and Methods: This retrospective study included 26 patients with advanced UC who received avelumab maintenance after first-line platinum-based chemotherapy between March 2021 and June 2025. Patients were grouped by induction regimen: full-dose gemcitabine/cisplatin (GC), reduced-dose GC, or gemcitabine/carboplatin (GCarbo). Survival outcomes from the start of avelumab treatment and from chemotherapy initiation were analyzed using the Kaplan-Meier method and compared using the Log rank test. Results: The median patient age was 72 years, with a significant difference among groups ( Conclusion: Avelumab maintenance showed comparable efficacy across the full-dose GC, reduced-dose GC, and GCarbo groups, highlighting the potential feasibility of personalized induction chemotherapy strategies. These findings may provide reassurance in clinical situations where full-dose cisplatin is not feasible due to patient frailty or renal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.